Comparative Pharmacology
Head-to-head clinical analysis: FABIOR versus TAZAROTENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABIOR versus TAZAROTENE.
FABIOR vs TAZAROTENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), inducing differentiation and apoptosis of keratinocytes.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
FABIOR (tazarotene) foam, 0.1%: Apply a thin layer once daily in the evening to affected areas of the face, scalp, or trunk.
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
None Documented
None Documented
Clinical Note
moderateTazarotene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Tazarotene."
Clinical Note
moderateTazarotene + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Nilotinib
Terminal elimination half-life is approximately 24-26 hours, supporting once-daily dosing.
Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days.
Primarily hepatic metabolism via CYP450; renal excretion of metabolites accounts for <1% of dose as unchanged drug. Fecal elimination is the major route (approximately 90%).
Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine.
Category C
Category D/X
Retinoid
Retinoid
"The metabolism of Nilotinib can be decreased when combined with Tazarotene."